[1] |
Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy[J] . Endocrinol Metab Clin North Am, 1995, 24(4):711-760.
|
[2] |
Xing M. BRAF mutation in thyroid cancer[J] . Endocr Relat Cancer, 2005, 12(2):245-262.
|
[3] |
Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage[J] . Nat Rev Mol Cell Biol, 2004, 5(11):875-885.
|
[4] |
Wojciechowska K, Lewinski A. BRAF mutations in papillary thyroid carcinoma[J] . Endocr Regul, 2006, 40(4):129-138.
|
[5] |
Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis [J] .Cancer, 2012, 118(7):1764-1773.
|
[6] |
Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer[J] . Ann Surg, 2007, 246(3):466-470.
|
[7] |
Wang YL,Zhang RW,Luo ZW,et al. High frequency of level Ⅱ-Ⅴ lymph node involvement in RET/PTC positive papillary thyroid carcinoma[J] . Eur J Surg Oncol, 2008,34(1):77-781.
|
[8] |
Kogan EA, Rozhkova EB, Seredin VP, et al. Prognostic value of the expression of thyreoglobulin and oncomarkers (p53, EGFR, ret-oncogene) in different types of papillary carcinoma of the thyroid: clinicomorphological and immunohistochemical studies[J] . Arkh Patol, 2006, 68(4):8-11.
|
[9] |
Musholt TJ, Fottner C, Weber MM, et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules[J] . World J Surg, 2010, 34(11):2595-2603.
|
[10] |
Henderson YC, Shellenberger TD, Williams MD, et al. High rate of BRAF and RET/PTC dual mutation associated with recurrent papillary thyroid carcinoma[J] . Clin Cancer Res, 2009, 15(2):485-491.
|
[11] |
Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm[J] . Endocrinol Metab Clin N Am, 2008, 37(2):419-435.
|
[12] |
Hamzany Y, Soudry E, Strenov Y. et al. Early death from papillary thyroid carcinoma[J] . Am J Otolaryngol, 2012, 33(1):104-108.
|
[13] |
Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity[J] . J Clin Endocrinol Metab, 2006, 91(9):3603-3610.
|
[14] |
Zafón C, Castellví J, Obiols G. Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis[J] . Endocrinol Nutr, 2010, 57(4):165-169.
|
[15] |
Tang KT, Lee CH. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications[J] . J Chin Med Assoc,2010, 73(3):113-128.
|
[16] |
Kakudo K, Bai YH, Katayama S. et al. Classification of follicular cell tumors of the thyroid gland: analysis invoving Japanese patients form one institute[J] . Pathol Int, 2009, 59(6):359-367.
|
[17] |
Nikiforov YE, Erickson LA, Nikiforova MN,et al. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior[J] . Am J Surg Pathol, 2001, 25(12):1478-1484.
|
[18] |
Silver CE, Owen RP, Rodrigo JP, et al. Aggressive variants of papillary thyroid carcinoma[J] . Head Neck, 2011, 33(7):1052-1059.
|
[19] |
Holler T, Theriault J, Payne RJ, et al. Prognostic factors in patients with multiple recurrences of well-differentiated thyroid carcinoma[J] . J Oncol, 2009, DOI:10.1155/2009/650340.
|